Article Listing - After a rough period, biotechs spring back in November, says Burrill report

DRUGS AND SWEDEN'S HEALTH BILL

6 April 1992

Sales of pharmaceutical products in Sweden totaled 10 billion krone ($1.6 billion) in 1990, an increase of 1 billion krone...

MAINTENANCE ULCER THERAPY CUT URGED

6 April 1992

A team of UK gastroenterologists have called for physicians to stop treating duodenal ulcer patients with maintenance H2 antagonist therapy....

WELLCOME SHARE FLOAT "MANAGERS"

6 April 1992

Following the recent announcement of its decision to float a further bank of shares in Wellcome plc, the Wellcome Trust...

BLOOD BANKING AND PLASMA PRODUCTS

6 April 1992

The world market for blood banking and plasma products was valued at $2.5 billion in 1990, and is expected to...

AUSTRALIAN VACCINE RESEARCH

6 April 1992

The Walter and Eliza Hall Institute of Medical research in Melbourne, Australia, is to set up a commercial joint venture...

MGI PHARMA'S SALAGEN

6 April 1992

MGI Pharma has gained orphan drug status from the US Food and Drug Administration for Salagen (pilocarpine), to treat dry...

MG FRANCE ATTACKS GOVT COST-CUTTING

6 April 1992

The association of doctors in France, MG France, has attacked the agreement on health care expenditures which has been...

INDIAN IBUPROFEN CHARGE DROPPED

6 April 1992

The US Department of Commerce has ceased its activities relating to claims of dumping and subsidies concerning imports into...

WALDEGRAVE GIVES MESSAGE TO UK PHARMA INDUSTY

6 April 1992

From UK Health Secretary William Waldegrave

As the UK's general election campaigning draws to a conclusion, Secretary of State for Health...

HUNGARIAN DRUGS "STILL COMPETITIVE"

6 April 1992

Despite the collapse of the Soviet market, Hungarian pharmaceutical companies have succeeded in making up for these lost sales by...